She lost 10kg of muscle and gained fat: The hidden risk of weight-loss drugs
Resumen detallado
Sydney doctor Dr Kean-Seng Lim’s waiting room is a stark reminder of the great potential, and the potential risks, of GLP-1s.
At a Mount Druitt medical practice where four in five patients are overweight and obese, a woman struggles to rise from her chair, her muscles having wasted away.
Dr Kean-Seng Lim’s western Sydney waiting room is a stark reminder of the great potential, and potential risks of GLP-1s such as Wegovy and Ozempic (semaglutide).
“They are powerful tools if used well, but they can be a double-edged sword,” said Lim, a GP for more than 30 years and a former Australian Medical Association NSW president.
A surge in demand for GLP-1 medications is expected to accelerate, with the first two oral GLP-1s – Novo Nordisk’s Wegovy pill and Lilly’s Foundayo – arriving at pharmacies for patients with private prescriptions.
GLP-1s, approved for chronic weight management when combined with diet and exercise, can be life-changing, triggering significant weight loss and lowering the risk of obesity-related health complications. Semaglutides have also been shown to lower the risk of heart attack, stroke and cardiovascular death.
But clinicians and researchers have cautioned against mistaking GLP-1s for a silver bullet, warning muscle wastage and a great weight rebound was on the horizon for those who do.
“But worryingly, the focus for these agents has been on weight, rather than health,” Lim said.
Kean-Seng recalled one of his patients, a woman aged over 60, who was having great difficulty getting out of her chair.
She had been prescribed GLP-1s via another provider with no follow-up or diet and exercise advice, reduced her food intake and, critically, wasn’t eating enough protein, Kean-Seng said.
Inicio del artículo, extracto de The Sydney Morning Herald. Para leer el resto, abra el artículo en el sitio del medio.
MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.smh.com.au)


